Skip to Content

Publications

Peer-Reviewed Original Research Articles 2009-Present

  1. Wang C, Mazumdar A, Mayer JA, Brown PH. SLC22A5/OCTN2 Expression in Breast Cancer is Induced by Estrogen via a Novel Intronic Estrogen-Response Element (ERE). Breast Cancer Research and Treatment. In Press.
  2. Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA. Cancer Preventive Rexinoid Modulates Neutral Lipid Content of Mammary Epithelial Cells through a PPAR-Gamma dependent Mechanism. Mol Pharmacol. e-Pub 11/2011.
  3. Uray IP, Brown PH. Chemoprevention of Hormone Receptor-negative Breast Cancer: New Approaches Needed. Recent Results Cancer Res(188):147-62, 2011.
  4. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen Induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor. Mol Endocrinol 25(9):1527-38, 2011. PMCID: PMC3165912.
  5. Gonzalez-Angulo AM, Hennessy BY, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Lei D, Broaddus R, Lluch AM, Aparicio S, Brown P, Pusztai L, Symmans F, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. PMCID: PMC3170272.
  6. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12(3):R40. e-Pub 6/2010. PMCID: PMC2917035.
  7. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 2010.
  8. Johnson KA, Brown PH. Drug Development for Cancer Chemoprevention: Focus on Molecular Targets. Semin Oncol 37(4):345-58, 2010.
  9. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107-13, 2009. PMCID: PMC2639315.
  10. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown PH. Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer. Clin Cancer Res 15(20):6327-40, 2009. PMCID: PMC2763053.
  11. Chen L, Krisko TI, Speers CW, Reif D, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Research 1:69(23):8853-61, 2009. PMCID: PMC2830975.
  12. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345-53, 2009. PMCID: PMC2610495.

© 2014 The University of Texas MD Anderson Cancer Center